BN
HealthAI Desk•3 views

FDA Proposes Excluding Novo, Lilly Weight Loss Drugs from Compounding List

The FDA has proposed excluding the active ingredients of major weight loss and diabetes drugs from Novo Nordisk and Eli Lilly from the list used for bulk compounding. This action aims to limit the creation of cheaper, compounded alternatives unless the drugs are officially designated as being in shortage. The agency cited a lack of "clinical need" for compounding these specific medications. The proposal affects 503B outsourcing facilities and is subject to public comment until late June. The move follows significant investments by the pharmaceutical companies to increase supply and improve affordability.

Ad slot
FDA Proposes Excluding Novo, Lilly Weight Loss Drugs from Compounding List

The U.S. Food and Drug Administration (FDA) has proposed excluding the active ingredients in blockbuster weight loss and diabetes medications from Novo Nordisk and Eli Lilly from the list available for bulk compounding. This move aims to restrict the creation of potentially cheaper, compounded alternatives unless the drugs are officially listed as being in shortage.

Key Details of the FDA Proposal

The proposal specifically targets the bulk compounding of several key medications. If finalized, the exclusion would significantly limit the ability of outsourcing facilities to manufacture custom, lower-cost versions of these drugs.

  • Affected Ingredients: The proposal covers several active ingredients, including:
    • Semaglutide: The active ingredient in Novo Nordisk's drugs, Wegovy (obesity) and Ozempic (diabetes).
    • Tirzepatide: The active ingredient in Eli Lilly's drugs, Zepbound (weight loss) and Mounjaro (diabetes).
    • Liraglutide: An older molecule drug from Novo Nordisk.
  • Rationale: The FDA stated it found "no clinical need" for outsourcing facilities to compound these drugs from bulk drug substances.
  • Scope: The proposal primarily affects 503B outsourcing facilities, which manufacture compounded drugs in bulk. It does not impact 503A pharmacies, which compound drugs based on individual patient prescriptions and are regulated largely at the state level.
Ad slot

Regulatory Implications and Timeline

FDA Commissioner Marty Makary emphasized that when FDA-approved drugs are available, compounding using bulk drug substances requires a "clear clinical need." The agency has indicated that it will consider public comments submitted until late June before making a final decision on the proposal.

Industry Impact and Company Response

This proposal comes as Novo Nordisk and Eli Lilly have invested billions into scaling up their manufacturing capacity, which has helped ease previous supply constraints. Furthermore, both companies have reportedly taken steps to improve the affordability of their branded medications to retain users who had previously turned to cheaper compounded options.

Ad slot